A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA
This study evaluates the safety and efficacy of baricitinib in participants with primary biliary cholangitis (PBC) who do not respond or are unable to take ursodeoxycholic acid (UDCA).
This trial stopped recruiting or enrolling participants prematurely and will not start again. We are no longer examining or treating participants. The trial may have been stopped for many reasons. You may contact Lilly for further information.
The study will last about 16 weeks and may include up to 7 visits.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participants must have a diagnosis of PBC
Participants must be taking UDCA in a stable dose or have previously taken, but are intolerant
Participants must not have other liver diseases including:
- Hepatitis C virus (HCV)
- Hepatitis B virus (HBV) infection
- Primary sclerosing cholangitis
- Alcoholic liver disease
- Autoimmune liver disease other than PBC, such as overlap hepatitis
- Nonalcoholic steatohepatitis
Participants must not have a history of VTE (deep vein thrombosis/pulmonary embolism [DVT/PE])
Participants must not have a current or recent clinically serious infection
Participants must not are receiving unstable treatment for pruritus
Participants must not have received obeticholic acid
Participants must not have received fenofibrate or other fibrates for the treatment of PBC